Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Globe Newswire 3-Dec-2024 8:00 AM

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.

• Praxis management will be participating in a fireside chat at the Piper Sandler 36^th Annual Healthcare Conference, taking place in New York, NY at the Lotte New York Palace Hotel on December 4, 2024 at 2:00pm ET. A live webcast of the event will be available through this link.
• Praxis management will also be participating in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts" at the Oppenheimer Movers in Rare Disease Summit, taking place in New York, NY at the Westin Grand Central Hotel on December 12, 2024 at 2:00pm ET.

The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective Piper Sandler and/or Oppenheimer representatives to request meetings.

The Piper Sandler live webcast will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website at www.praxismedicines.com. Following the event, a replay will be posted, when available, to Praxis' website on the "Events and Presentations" page under the investor section of the website for 90 days.

About Praxis? 
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576